Net Loss per Share - Schedule of computation of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Numerator
Net loss	$ (35,333)	$ (36,909)
Less: Net loss attributable to noncontrolling interest	$ (25,841)	$ (27,244)
Antidilutive securities
Earnout Rights	17,500,000	17,500,000
Stock options granted under the 2022 Equity Incentive Plan	21,845,327	14,591,415
Restricted Stock Rights [Member]
Antidilutive securities
Unvested Restricted Stock Rights	2,312,356	6,175,541
Legacy SCS [Member]
Antidilutive securities
Legacy SCS Restricted Share Units	0	50,000
Common Class A [Member]
Numerator
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Basic	$ (9,492)	$ (9,665)
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Diluted	$ (9,492)	$ (9,665)
Denominator
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Basic	60,951,721	61,540,231
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Diluted	60,951,721	61,540,231
Net loss per share attributable to Class A ordinary shares, Basic	$ (0.16)	$ (0.16)
Net loss per share attributable to Class A ordinary shares, Diluted	$ (0.16)	$ (0.16)
Antidilutive securities
ProKidney Corp. ordinary shares	61,621,330		59,880,347
Common Class B [Member]
Antidilutive securities
ProKidney Corp. ordinary shares	167,723,553	173,444,861	168,297,916